171 related articles for article (PubMed ID: 2808210)
21. [Antimicrobial susceptibilities of organisms isolated from patients with urinary tract infections in 2002].
Eta S; Kawahara M
Jpn J Antibiot; 2006 Feb; 59(1):21-8. PubMed ID: 16673579
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
23. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002].
Yamaguchi K; Ishii Y; Iwata M; Yoshida H; Satoh T; Watanabe N; Uehara N; Murakami M; Takahashi A; Yasujima M; Kasai T; Itoh K; Shibuya Y; Suwabe A; Obata R; Kanno H; Kubo S; Kaku M; Kanemitsu K; Maesaki S; Hashikita G; Igari J; Oguri T; Aihara M; Kinoshita S; Okada J; Tazawa Y; Taminato T; Negayama K; Nakashima H; Takemura H; Murase M; Miyamoto H; Horii T; Kusano N; Mihara E; Baba H; Ishigo S; Kambe M; Itaha H; Fujita N; Komori T; Ono J; Yoshimura H; Ichiyama S; Maeda S; Hirakata Y; Matsuda J; Yamanaka K; Murata Y; Saikawa T; Hiramatsu K
Jpn J Antibiot; 2004 Feb; 57(1):70-104. PubMed ID: 15116574
[TBL] [Abstract][Full Text] [Related]
24. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Watt B; Naden M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
[TBL] [Abstract][Full Text] [Related]
25. In vitro synergistic activity between meropenem and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Sumita Y; Mitsuhashi S
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):77-84. PubMed ID: 1864279
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
[TBL] [Abstract][Full Text] [Related]
27. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
28. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Shinagawa M; Yasujima M; Suwabe A; Kuroda M; Kaku M; Kitagawa M; Kanemitsu K; Imafuku Y; Murakami M; Yomodu S; Taniguchi N; Yamada T; Nomura F; Kanno H; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Horikawa Y; Maekawa M; Nagura O; Yagi T; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kawano S; Kinoshita S; Taminato T; Negayama K; Murase M; Miyamoto H; Kusano N; Nose M; Yokozaki M; Itaha H; Matsunaga A; Yoshimura H; Kohno S; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
Jpn J Antibiot; 2011 Apr; 64(2):53-95. PubMed ID: 21721247
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
[No Abstract] [Full Text] [Related]
30. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 2001 Jul; 48(1):23-8. PubMed ID: 11418509
[TBL] [Abstract][Full Text] [Related]
32. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Wiedemann B; Zühlsdorf M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
[TBL] [Abstract][Full Text] [Related]
33. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):157-63. PubMed ID: 9327242
[TBL] [Abstract][Full Text] [Related]
34. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
Kitzis MD; Acar JF; Gutmann L
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
Hornsey M; Phee L; Stubbings W; Wareham DW
Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of BMS-181139, a new carbapenem with potent antipseudomonal activity.
Kessler RE; Fung-Tomc J; Kolek B; Minassian B; Huczko E; Gradelski E; Bonner DP
Antimicrob Agents Chemother; 1995 Feb; 39(2):380-5. PubMed ID: 7726502
[TBL] [Abstract][Full Text] [Related]
37. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Tasaka K; Ishida A; Chinzei T
Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
[TBL] [Abstract][Full Text] [Related]
38. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
[TBL] [Abstract][Full Text] [Related]
39. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
Ermertcan S; Hoşgör M; Tünger O; Coşar G
Scand J Infect Dis; 2001; 33(11):818-21. PubMed ID: 11760161
[TBL] [Abstract][Full Text] [Related]
40. In-vitro activity of a new penem FCE 22101.
Hoban DJ
J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
